Statements and Voting Guidance from Major Investors May Offer Companies a Roadmap For What Lies Ahead
Published 05-02-22
Submitted by Boston Scientific
Originally Published by Corporate Compliance Insights
By Mai-Khoi Nguyen-Thanh and Taylor Wirth
Intense focus on the environmental prong of ESG is being driven by a constellation of private actors. Institutional investors, in particular, are making their voices heard through the 2022 proxy season by urging companies to demonstrate meaningful progress on climate and environmental sustainability. And in fact, many companies are already doing so in an effort to distinguish themselves in the competition for customers, talent and investor funds.
Beyond simply complying with changing regulatory minimum standards, making ESG a priority should include watching for signals from institutional investors, proxy advisors and other advocacy groups.
Every business will have its own focus with respect to environmental practices. But in general, the following approaches can help your organization maintain a positive relationship with investors while progressing toward your goals:
Continue reading here
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
More from Boston Scientific